The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and the Drugs for Neglected Diseases initiative (DNDi) to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.
Medicines for Malaria Venture (MMV)
See the following -
3Rs For Innovating Novel Antibiotics: Sharing Resources, Risks, And Rewards
Anthony D So, Quentin Ruiz-Esparza, Neha Gupta, Otto Cars | BMJ | April 3, 2012
The stream of new antibiotics is struggling to keep up with emerging bacterial resistance. Anthony So and colleagues examine what can be done to increase innovation... Read More »
- Login to post comments
Advancing Antimalarial Drug Research Through Open Source Initiatives
Jeremy Burrows | The Guardian | July 24, 2013
Open research can lead to new drugs tackling diseases that afflict the world's poor. But first, more scientists need to buy into contributing to something bigger than their careers Read More »
- Login to post comments
Africa: Partners Commit To Bolster Open Source Research
Press Release |
Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), Royal Society of Chemistry (RSC) |
November 27, 2013
The Royal Society of Chemistry (RSC), UK, Drugs for Neglected Diseases initiative (DNDi) and MMV have signed a memorandum of understanding (MoU) to collaborate in an effort to build a global community of researchers contributing to open source drug discovery for diseases of poverty. Read More »
- Login to post comments
Africa: Potential New Class Of Antimalarials Now Open Source
Staff Writer | allAfrica | September 10, 2013
This week, MMV hands the triazolopyrazines and their key data over to Dr Mat Todd at the University of Sydney, where research on these potential antimalarials will continue for all the world to see as part of the Open Source Malaria project. Read More »
- Login to post comments
Celebrating Generation Open – Open Data Institute Awards Network Thinkers Who Are Changing The World
By Patrice John-Baptiste | July 12, 2015
On Thursday, July 9, the Open Data Institute (ODI) celebrated its second annual Open Data Awards, at Bloomberg London, celebrating a generation of network thinkers who are changing the world with open data. Awarded by ODI Co-founders, Sir Tim Berners-Lee and Sir Nigel Shadbolt, 300 delegates convened to recognise today’s open data champions creating real world impact. From Kenya, Uruguay and Indonesia, to Brussels, Italy, and Ukraine, the ODI received over 500 nominations commending unsung heroes working with open data worldwide. Read More »
- Login to post comments
Funding Crunch Hits Neglected Diseases Plan
Staff Writer | SciDev.Net | April 29, 2014
The Open Source Drug Discovery (OSDD) programme — a global collaborative initiative supported by the Indian government to find affordable treatment for neglected tropical diseases — has suffered a temporary setback due to a funds crunch caused by tardy submission of funding estimates. Read More »
- Login to post comments
Funds Crunch Hits India's Drug Development Project
Joe C. Mathew | Business World | April 5, 2014
Lack of funds is threatening the smooth progress of India’s unique Open Source Drug Discovery (OSDD) project, a first of its kind attempt to develop drugs for neglected diseases, when it is entering a crucial phase of research. Prime Minister Manmohan Singh had in February announced that OSDD, the pet project of the Council of Scientific and Industrial Research (CSIR), had identified a lead (potential drug candidate) for tuberculosis (TB).
- Login to post comments
International Team of Scientists Open Sources Search for Malaria Cure
By Alice Williamson | June 21, 2014
The Open Source Malaria (OSM) project operates along very similar lines to traditional medicinal chemistry projects in that the team is looking for an antimalarial drug candidate suitable for Phase 1 clinical trials. However, the day to day running of the project works quite differently and is probably most clearly defined by the team’s commitment to The Six Laws of Open Science... Read More »
- Login to post comments
Medicines for Malaria Venture Releases Report on how R&D Partnerships Serving Neglected Communities have Developed Dozens of Life-Saving Innovations Since 2010
Press Release |
Medicines for Malaria Venture |
January 28, 2021
The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for accelerating biomedical innovation. This is another powerful example of how public-private partnerships have established themselves as powerhouses for fighting global health threats. According to a new report launched today from a group of 12 product development partnerships (PDPs), over the last decade, such alliances have brought to market 66 new drugs, vaccines, diagnostics and other technologies for a number of diseases—including tuberculosis, malaria, HIV, meningitis and sleeping sickness. These innovations have reached and benefitted more than 2.4 billion people in low-income countries.
- Login to post comments
New Open Source Drug Discovery Project Aims to Develop Mycetoma Treatment
Press Release |
ErasmusMC , University of Sydney , DNDi |
February 6, 2018
- Login to post comments
Open Access Initiative Reveals Drug Hits For Deadly Neglected Tropical Diseases
Press Release |
Drugs for Neglected Diseases initiative (DNDi), Medicines for Malaria Venture (MMV) |
November 13, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi’s screening of MMV’s open access Malaria Box. Read More »
- Login to post comments
Recent Research Highlights Potential Of Open Access In Drug Discovery
Rachel Marusak Hermann | Intellectual Property Watch | November 14, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain. Read More »
- Login to post comments
Copyright ©2011-2020 Open Health Marketplace, LLC. All Rights Reserved.